Lennox-Gastaut syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Apr 2026

LAMOTRIGINE: New indication approved

FDAcompleted
Apr 2026

LAMOTRIGINE KIT: New indication approved

FDAcompleted
Apr 2026

LAMOTRIGINE: New indication approved

FDAcompleted
Apr 2026

LAMOTRIGINE: New indication approved

FDAcompleted
Mar 2026

LAMOTRIGINE: New indication approved

FDAcompleted
Mar 2026

TOPIRAMATE: New indication approved

FDAcompleted
Mar 2026TROKENDI XR: New indication approved
FDAcompleted
Mar 2026TOPAMAX: New indication approved
FDAcompleted
Mar 2026EPRONTIA: New indication approved
FDAcompleted
Mar 2026TOPAMAX: New indication approved
FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

5 programs

FINANCIAL LANDSCAPE SUMMARY

5

Total programs

5

Open now

2

Copay cards

Copay Assistance2

Onfi

Lundbeck

OpenContact for detailsApply ↗

Lamictal

Glaxo Wellcome Research and Development

OpenContact for details

Patient Assistance Programs3

Epidiolex

Jazz Pharmaceuticals, Inc.

OpenContact for detailsApply ↗

Banzel

Eisai, Inc.

OpenContact for details

Fintepla

UCB, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

7 FDA-approved

Fintepla

(fenfluramine)Orphan drug

UCB, Inc.

12.1 Mechanism of Action The precise mechanism by which fenfluramine exerts its therapeutic effects in the treatment of seizures associated with Drave...

Approved Mar 2022FDA label ↗

Epidiolex

(CANNABIDIOL)Orphan drug

Jazz Pharmaceuticals, Inc.

12.1 Mechanism of Action The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear...

Approved Sep 2018FDA label ↗

Onfi

(clobazam)Orphan drug

Lundbeck, Inc.

Benzodiazepine [EPC]

12.1 Mechanism of Action The exact mechanism of action for clobazam, a 1,5-benzodiazepine, is not fully understood but is thought to involve potentiat...

Approved Oct 2011FDA label ↗

Banzel

(rufinamide)Orphan drug

Eisai, Inc.

12.1 Mechanism of Action The precise mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. The results of in vitro studies sugg...

Approved Nov 2008FDA label ↗

Topamax

(Topiramate)Orphan drug

Johnson & Johnson Pharmaceutical R & D, LLC

12.1 Mechanism of Action The precise mechanisms by which topiramate exerts its anticonvulsant and preventive migraine effects are unknown; however, pr...

Approved Aug 2001FDA label ↗

Lamictal

(Lamotrigine)Orphan drug

Glaxo Wellcome Research and Development

Anti-epileptic Agent [EPC]

12.1 Mechanism of Action The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to dete...

Approved Aug 1998FDA label ↗

Felbamate

(FELBAMATE)Orphan drug

Taro Pharmaceuticals U.S.A., Inc.

Anti-epileptic Agent [EPC]

Mechanism of Action The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anti...

Approved Jul 1993FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

5 active trials
1Phase 3
1Phase 4
1N/A
2Unknown
5Total recruiting
Search clinical trials for Lennox-Gastaut syndrome

Recent News & Research

6 articles
Epileptic disorders : international epilepsy journal with videotapeApr 16, 2026

A temporary spike: Investigating Lennox-Gastaut syndrome incidence in the US following FDA approval of cannabidiol.

In June 2018, the US Food and Drug Administration (FDA) approved pharmaceutical grade cannabidiol (CBD; Epidiolex®) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). We...

Read ↗
SeizureApr 14, 2026

Soticlestat for drug-resistant epilepsy: Current evidence and clinical perspectives.

Epilepsy, particularly drug-resistant epilepsy, remains a significant clinical challenge, with many patients failing to achieve seizure control through conventional antiseizure medications. This unmet...

Read ↗
Seminars in pediatric neurologyApr 10, 2026

EEG findings in Lennox-Gastaut syndrome: Pursuing a moving target.

Lennox-Gastaut Syndrome (LGS) is a life-long, drug-resistant developmental epileptic encephalopathy (DEE) that develops in young children between 18 and 24 months of age and up to 18 years of age. The...

Read ↗
Neuromodulation : journal of the International Neuromodulation SocietyApr 8, 2026

Systematic Review and Meta-Analysis of Bilateral Centromedian Nucleus Neuromodulation for Multifocal and Generalized Epilepsy.

Generalized and multifocal forms of drug-resistant epilepsy are highly prevalent but have limited treatment options. Centromedian nucleus (CMN) thalamic neuromodulation has emerged as an effective tre...

Read ↗
Neuromodulation : journal of the International Neuromodulation SocietyApr 8, 2026

Invasive Neuromodulation in Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.

Lennox-Gastaut syndrome (LGS) is a highly drug-resistant epileptic encephalopathy. The high seizure burden in LGS contributes to substantial morbidity, reduced quality of life, and increased mortality...

Read ↗
EpilepsiaApr 7, 2026

Charlotte Dravet: Life and contributions to epileptology.

Charlotte Dravet: Life and contributions to epileptology.

Read ↗

Browse all Lennox-Gastaut syndrome news →

Specialist Network

Top 6 by expertise

View all Lennox-Gastaut syndrome specialists →

Quick Actions